Teva Pharmaceutical Industries (NYSE:TEVA) Now Covered by Analysts at Barclays

Barclays began coverage on shares of Teva Pharmaceutical Industries (NYSE:TEVA) in a research report released on Tuesday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $35.00 price target on the stock.

A number of other equities analysts have also recently weighed in on the company. Scotiabank assumed coverage on Teva Pharmaceutical Industries in a report on Friday, December 5th. They issued a “sector outperform” rating and a $35.00 price target for the company. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, October 8th. UBS Group boosted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday, September 24th. Finally, The Goldman Sachs Group raised their target price on Teva Pharmaceutical Industries from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Monday. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $30.25.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $28.56 on Tuesday. The company has a debt-to-equity ratio of 2.31, a current ratio of 1.11 and a quick ratio of 0.82. Teva Pharmaceutical Industries has a 1-year low of $12.47 and a 1-year high of $29.10. The company has a market capitalization of $32.75 billion, a price-to-earnings ratio of 47.59, a PEG ratio of 1.52 and a beta of 0.67. The business has a 50-day moving average of $22.83 and a 200-day moving average of $19.37.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 200,000 shares of the firm’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $24.11, for a total transaction of $4,822,000.00. Following the completion of the transaction, the director directly owned 495,000 shares of the company’s stock, valued at $11,934,450. This trade represents a 28.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.55% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Large investors have recently modified their holdings of the stock. Cetera Investment Advisers raised its stake in Teva Pharmaceutical Industries by 2.5% during the first quarter. Cetera Investment Advisers now owns 54,430 shares of the company’s stock valued at $837,000 after buying an additional 1,325 shares in the last quarter. LPL Financial LLC increased its holdings in shares of Teva Pharmaceutical Industries by 5.5% in the 1st quarter. LPL Financial LLC now owns 213,280 shares of the company’s stock valued at $3,278,000 after acquiring an additional 11,029 shares during the last quarter. US Bancorp DE increased its holdings in shares of Teva Pharmaceutical Industries by 6.5% in the 1st quarter. US Bancorp DE now owns 10,812 shares of the company’s stock valued at $166,000 after acquiring an additional 656 shares during the last quarter. PNC Financial Services Group Inc. raised its position in shares of Teva Pharmaceutical Industries by 2.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 59,647 shares of the company’s stock valued at $917,000 after acquiring an additional 1,578 shares in the last quarter. Finally, Blair William & Co. IL lifted its stake in Teva Pharmaceutical Industries by 67.2% during the first quarter. Blair William & Co. IL now owns 18,782 shares of the company’s stock worth $289,000 after purchasing an additional 7,550 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.